Pfizer’s efforts will span small molecule therapeutics ... Among the new phase 3 starts are CDK4 inhibitor atirmociclib as a second-line therapy for hormone receptor-positive metastatic breast ...

Arvinas and Pfizer have shared preliminary outcomes from ... all of whom had previously been treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. No significant drug-drug interactions ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Pfizer already makes big revenues from its breast ... The phase 3 PENELOPE-B trial was testing the CDK4/6 inhibitor as a potential treatment for early breast cancer patients who have residual ...